LEADER 06021nam 2200613Ia 450 001 9910817058303321 005 20200520144314.0 010 $a1-280-20360-9 010 $a9786610203604 010 $a0-309-59763-3 010 $a0-585-14901-1 035 $a(CKB)111004366660606 035 $a(OCoLC)43477116 035 $a(CaPaEBR)ebrary10056851 035 $a(SSID)ssj0000215893 035 $a(PQKBManifestationID)11216875 035 $a(PQKBTitleCode)TC0000215893 035 $a(PQKBWorkID)10194722 035 $a(PQKB)10886702 035 $a(MiAaPQ)EBC3376577 035 $a(Au-PeEL)EBL3376577 035 $a(CaPaEBR)ebr10056851 035 $a(CaONFJC)MIL20360 035 $a(OCoLC)49853767 035 $a(EXLCZ)99111004366660606 100 $a19910513d1991 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aOral contraceptives & breast cancer /$fCommittee on the Relationship Between Oral Contraceptives and Breast Cancer, Institute of Medicine, Division of Health Promotion and Disease Prevention 205 $a1st ed. 210 $aWashington, D.C. $cNational Academy Press$d1991 215 $a1 online resource (195 p.) 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-309-04493-6 320 $aIncludes bibliographical references and index. 327 $aOral Contraceptives & -- Breast Cancer -- Copyright -- Preface -- Contents -- Executive Summary -- MAINTAINING SURVEILLANCE -- DEVELOPING A BROADER ARRAY OF CONTRACEPTIVES -- ASSESSING KNOWLEDGE FOR APPLICATION IN CLINICAL PRACTICE -- FILLING GAPS IN BIOLOGICAL AND EPIDEMIOLOGICAL KNOWLEDGE -- 1 Introduction and Overview -- BIOLOGICAL PLAUSIBILITY OF A LINK BETWEEN ORAL CONTRACEPTIVES AND BREAST CANCER -- WHAT IS-AND IS NOT-KNOWN -- SEEKING ANSWERS -- 2 Epidemiology: Information Needs and Data Gaps -- EPIDEMIOLOGICAL RESEARCH -- Case-Control Method -- Cohort Studies -- Comparison Groups -- Ecological Studies -- Special Studies -- Women Exposed to Hormones Other than Oral Contraceptives -- Women Genetically Susceptible to Breast Cancer -- Estrogen Metabolism -- Progestins -- Changing Oral Contraceptive Formulations -- SUMMARY AND CONCLUSIONS -- 3 Biology: Information Needs and Data Gaps -- SIGNAL COMPLEXITY IN BREAST REGULATION -- RESEARCH ISSUES -- Relationships Among Cell Types -- Receptors -- Timing -- Effects of Pregnancy and Lactation -- Pathological Breast Tissue -- Oncogenes -- Molecular Changes Associated with Human Breast Cancer -- Activated ras Mutations -- Overexpression of Tyrosine Kinases -- Amplification of int-2 and myc -- Deletions of Genes -- RESEARCH MODELS -- Breast Cancer Cell Lines -- Short-term Culture of Normal Mammary Epithelium -- Organ Culture -- Nude Mouse Model -- SUMMARY AND CONCLUSIONS -- 4 Information for Users of the Pill and Health Care Providers -- BENEFITS AND RISKS OF ORAL CONTRACEPTIVES -- Benefits -- Risks -- CURRENT CONTROVERSY -- PRESCRIBING PROBLEMS -- 5 Policy Issues and Recommendations -- MAINTAINING SURVEILLANCE -- Cooperative Research -- Surveillance Requirements of the Food and Drug Administration -- DEVELOPING A BROADER ARRAY OF CONTRACEPTIVES. 327 $aASSESSING KNOWLEDGE FOR APPLICATION IN CLINICAL PRACTICE -- FILLING GAPS IN BIOLOGICAL AND EPIDEMIOLOGICAL KNOWLEDGE -- References -- Appendixes -- A Oral Contraceptives and Breast Cancer: A Review of the Epidemiological Evidence with an Emphasis ... -- Changing Profile Of Oral Contraceptive Use -- Biological Plausibility -- Epidemiological Studies Of Breast Cancer and Oral Contraceptives -- Ever" Use of Oral Contraceptives -- Duration of Oral Contraceptive Use -- Oral Contraceptive Use Before First Full-term Pregnancy or Before Age 25 -- Duration Since First Use of Oral Contraceptives (Latency) -- Use of Oral Contraceptives in High-Risk Subgroups -- Steroidal Potency of Various Formulations -- Issues to Consider in Reviewing the Epidemiological Evidence -- Discussion -- The Future -- References -- B Oral Contraceptives and Breast Cancer: Review of the Epidemiological Literature -- Methods -- Results -- Risk of Oral Contraceptive Users of All Ages in Developed Countries -- Risk in Oral Contraceptive Users in Developing Countries -- Risk in Oral Contraceptive Users With and Without Various Risk Factors for Breast Cancer -- Risk in Relation to Early Use of Oral Contraceptives -- Screening Bias -- Risk in Relation to Use of Oral Contraceptives Near the Age of Menopause -- Individual Formulations and Constituents of Oral Contraceptives -- Conclusions, Interpretations, and Recommendations for Further Research -- Acknowledgments -- References -- C The Evolving Formulations of Oral Contraceptives -- Implications for Research -- References -- D Animal Models of Sex Steroid Hormones and Mammary Cancer: Lessons for Understanding Studies in Humans -- Direct Tests of Carcinogenicity -- Mice and Rats -- Beagle Dogs -- Pharmacokinetics of Various Steroids in Mice, Rats, and Beagles. 327 $aStudies of Mechanisms for Mammary Carcinogenicity of Sex Steroid Hormones in Mice, Rats, and Dogs -- Conclusions -- Interesting Questions Raised by Animal Studies -- References -- E Risks and Benefits of Oral Contraceptives: Will Breast Cancer Tip the Balance? -- Established Benefits and Risks -- Balance of Benefits and Risks -- Oral Contraceptives and Breast Cancer -- An Effect in Young Women -- Conclusions -- References -- F List of Background Documents -- Index. 517 1 $aOral contraceptives and breast cancer 606 $aBreast$xCancer$xEpidemiology$vCongresses 606 $aOral contraceptives$xSide effects$vCongresses 615 0$aBreast$xCancer$xEpidemiology 615 0$aOral contraceptives$xSide effects 676 $a616.99/449071 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910817058303321 996 $aOral contraceptives & breast cancer$94126198 997 $aUNINA